58519-43-0

Basic information

• Product Name: ethyl 4-((quinolin-4-yl)amino)benzoate
• Synonyms: ethyl 4-((quinolin-4-yl)amino)benzoate
• CAS NO: 58519-43-0
• Molecular Weight: 292.337
• Mol File: 58519-43-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: ethyl 4-((quinolin-4-yl)amino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-((quinolin-4-yl)amino)benzoate(58519-43-0)
• EPA Substance Registry System: ethyl 4-((quinolin-4-yl)amino)benzoate(58519-43-0)

Safety Data

• Hazardous Substances Data: 58519-43-0(Hazardous Substances Data)

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 3964-04-3 4-bromoquinoline 
• 611-36-9 quinolin-4-ol 
• 611-35-8 4-chloroquinoline 

Relevant articles and documents

Discovery and SAR study of piperidine-based derivatives as novel influenza virus inhibitors

A series of piperidine-based derivatives were identified as novel and potent inhibitors of the influenza virus through structural modification of a compound that was selected from a high-throughput screen. Various analogues were synthesized and confirmed as inhibitors. The structure-activity relationship (SAR) studies suggested that the ether linkage between the quinoline and piperidine is critical for the inhibitory activity. The optimized compound tert-butyl 4-(quinolin-4-yloxy)piperidine-1-carboxylate 11e had an excellent inhibitory activity against influenza virus infection from a variety of influenza virus strains, with EC50values as low as 0.05 μM. The selectivity index value (SI = MLD50/EC50) of 11e is over 160 000 based on cytotoxicity, measured by MTT assays of three cell lines. We carried out a time-of-addition experiment to delineate the mechanism of inhibition. The result indicates that 11e interferes with the early to middle stage of influenza virus replication.

Discovery of a Nur77-mediated cytoplasmic vacuolation and paraptosis inducer (4-PQBH) for the treatment of hepatocellular carcinoma

Nur77, an orphan nuclear receptor, has antitumor activity in hepatocellular carcinoma (HCC). However, its antitumor mechanisms of action in HCC are complicated and rarely reported. Our recent work demonstrated that certain quinoline-Schiff-base derivatives were good Nur77 mediators that exerted excellent anti-HCC activities in vitro and in vivo. Interestingly, these compounds shared similar chemical structures, but they displayed different Nur77-targeted anticancer mechanisms of action. As a continuous work, we synthesized a series of 4-(quinoline-4-amino) benzoylhydrazide derivatives and evaluated their anti-HCC activity and binding affinity to Nur77 in vitro. Compound 4-PQBH emerged as the best Nur77 binder (KD = 1.17 μM) and has potentially selective cytotoxicity to HCC cells. Mechanistically, 4-PQBH extensively induced caspase-independent cytoplasmic vacuolization and paraptosis through Nur77-mediated ER stress and autophagy. Moreover, 4-PQBH exhibited an effective xenograft tumor inhibition by modulating Nur77-dependent cytoplasmic vacuolation and paraptosis. This paper is the first to disclose that chemotherapeutic agents targeting Nur77-mediated cytoplasmic vacuolization and paraptosis may provide a promising strategy to combat HCC that frequently evade the apoptosis program.

4-((2-substituted quinoline-4-yl)amino)benzoyl hydrazine derivatives as well as preparation method and application thereof

The invention relates to 4-((2-substituted quinoline-4-yl)amino)benzoyl hydrazine derivatives as well as a preparation method and application thereof, which relate to N'-substituted methylene-4-((2-substituted quinoline-4-yl)amino)benzoyl hydrazine deriva